What is a stock summary page? Click here for an overview.
Business Description
Addex Therapeutics Ltd
ISIN : US00654J2069
Share Class Description:
ADXN: ADRCompare
Compare
Traded in other countries / regions
ADXN.SwitzerlandADXNz.UKADXN.USAAPE1.Germany IPO Date
2020-01-29Description
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 76.23 | |||||
| Equity-to-Asset | 0.91 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -39.55 | |||||
| Beneish M-Score | 34.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -45.4 | |||||
| 3-Year EBITDA Growth Rate | 33.3 | |||||
| 3-Year EPS without NRI Growth Rate | 33.3 | |||||
| 3-Year FCF Growth Rate | 38.3 | |||||
| 3-Year Book Growth Rate | -74.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -22.42 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.21 | |||||
| 9-Day RSI | 49.97 | |||||
| 14-Day RSI | 49.45 | |||||
| 3-1 Month Momentum % | 12.62 | |||||
| 6-1 Month Momentum % | -11.85 | |||||
| 12-1 Month Momentum % | -23.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.59 | |||||
| Quick Ratio | 4.59 | |||||
| Cash Ratio | 3.78 | |||||
| Days Sales Outstanding | 194.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -66.5 | |||||
| Shareholder Yield % | 2.46 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1995.86 | |||||
| Net Margin % | 973.87 | |||||
| FCF Margin % | -1067.41 | |||||
| ROE % | 98.53 | |||||
| ROA % | 67.59 | |||||
| ROIC % | -276.65 | |||||
| 3-Year ROIIC % | -216.8 | |||||
| ROC (Joel Greenblatt) % | -7907.5 | |||||
| ROCE % | -220.64 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 1.85 | |||||
| PS Ratio | 15.19 | |||||
| PB Ratio | 0.68 | |||||
| Price-to-Tangible-Book | 0.68 | |||||
| EV-to-EBIT | -0.29 | |||||
| EV-to-EBITDA | -0.31 | |||||
| EV-to-Revenue | 6.76 | |||||
| EV-to-Forward-Revenue | 5.93 | |||||
| EV-to-FCF | -0.69 | |||||
| Price-to-GF-Value | 2.03 | |||||
| Price-to-Net-Current-Asset-Value | 3.04 | |||||
| Price-to-Net-Cash | 3.04 | |||||
| Earnings Yield (Greenblatt) % | -344.83 | |||||
| FCF Yield % | -84.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ADXN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Addex Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.632 | ||
| EPS (TTM) ($) | -0.306 | ||
| Beta | 1.63 | ||
| 3-Year Sharpe Ratio | -0.24 | ||
| 3-Year Sortino Ratio | -0.39 | ||
| Volatility % | 72.93 | ||
| 14-Day RSI | 49.45 | ||
| 14-Day ATR ($) | 0.670505 | ||
| 20-Day SMA ($) | 7.72675 | ||
| 12-1 Month Momentum % | -23.21 | ||
| 52-Week Range ($) | 6.67 - 27.9 | ||
| Shares Outstanding (Mil) | 1.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Addex Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Addex Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Addex Therapeutics Ltd Frequently Asked Questions
What is Addex Therapeutics Ltd(ADXN)'s stock price today?
The current price of ADXN is $7.50. The 52 week high of ADXN is $27.90 and 52 week low is $6.67.
When is next earnings date of Addex Therapeutics Ltd(ADXN)?
The next earnings date of Addex Therapeutics Ltd(ADXN) is .
Does Addex Therapeutics Ltd(ADXN) pay dividends? If so, how much?
Addex Therapeutics Ltd(ADXN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers